| Filed On | Filing |
|---|---|
| 03 Nov 2026 | 10-Q |
| 03 Nov 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Q3 2026 total product revenue of $125.5 million, reflecting 19% growth year-over-year |
| 25 Aug 2026 |
Form 4: Hohenleitner Susan, Chief Financial Officer
Sold 1,558 shares ($6.01K) |
| 25 Aug 2026 |
Form 4: Reilly Joseph James, See Remarks
Sold 3,982 shares ($15.4K) |
| 25 Aug 2026 |
Form 4: Bishop John E, See Remarks
Sold 19,750 shares ($76.2K) |
| 25 Aug 2026 |
Form 4: Brady James Parker, Chief Human Resources Officer
Sold 15,136 shares ($58.4K) |
| 25 Aug 2026 |
Form 4: Foster Eric Duane, Chief Commercial Officer
Sold 8,562 shares ($33K) |
| 25 Aug 2026 |
Form 4: Kelliher Mike, Chief Business Officer
Sold 7,758 shares ($29.9K) |
| 25 Aug 2026 |
Form 4: Williams Laura A, Chief Patient Officer
Sold 10,739 shares ($41.4K) |
| 25 Aug 2026 |
Form 4: Raab Michael, Director
Sold 58,574 shares ($226K) |
| 21 Aug 2026 | 144 |
| 21 Aug 2026 | 144 |
| 21 Aug 2026 | 144 |
| 21 Aug 2026 | 144 |
| 21 Aug 2026 | 144 |
| 21 Aug 2026 | 144 |
| 21 Aug 2026 | 144 |
| 21 Aug 2026 | 144 |
| 17 Aug 2026 |
8-K: Other Events
On August 11, 2026, Eric Foster notified Ardelyx, Inc. (the “Company”) of his decision to resign as Chief Commercial Officer of the Company, effective August 28, 2026. Mr. Foster resigned to pursue a new opportunity with a pre-commercial... |
| 14 Aug 2026 | SCHEDULE 13G |
Loading...